Mustang Bio (MBIO) Profit After Tax (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Profit After Tax of -$955000.0 for Q1 2026, down 524.18% year-over-year from $225138.7 in Q1 2025, and down 77.51% quarter-over-quarter from -$538000.0 in Q4 2025.
Mustang Bio (MBIO) Profit After Tax (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Profit After Tax for 11 consecutive years, with -$955000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 524.18% year-over-year to -$955000.0; the TTM figure through Mar 2026 stood at -$2.7 million (up 74.58% YoY), while the FY2025 annual figure was -$1.9 million, up 87.8% from the prior year.
- Profit After Tax slipped to -$955000.0 in Q1 2026 per MBIO's latest filing, from -$538000.0 in the prior quarter.
- Across five years, Profit After Tax topped out at -$153000.0 in Q1 2025 and bottomed at -$19.8 million in Q1 2022.
- Historically, Profit After Tax has averaged -$8.7 million across 5 years, with a median of -$8.2 million in 2024.
- Annual changes were most pronounced in 2025 — Profit After Tax soared 97.05% — and 2026, when it plunged 524.18%.
- Mustang Bio's Profit After Tax stood at -$19.6 million in 2022, then surged by 56.12% to -$8.6 million in 2023, then jumped by 88.95% to -$952000.0 in 2024, then jumped by 43.49% to -$538000.0 in 2025, then slumped by 77.51% to -$955000.0 in 2026.
- Business Quant data shows MBIO's Profit After Tax at -$955000.0 in Q1 2026, -$538000.0 in Q4 2025, and -$468000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | -1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.07 Mn |
| Mar 31, 2026 | -955,000.00 |
| Dec 31, 2025 | -538,000.00 |
| Sep 30, 2025 | -468,000.00 |
| Jun 30, 2025 | -762,000.00 |
| Mar 31, 2025 | -153,000.00 |
| Dec 31, 2024 | -952,000.00 |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -8.20 Mn |
| Mar 31, 2024 | -5.19 Mn |
| Dec 31, 2023 | -8.62 Mn |
| Sep 30, 2023 | -10.06 Mn |
| Jun 30, 2023 | -16.24 Mn |
| Mar 31, 2023 | -16.69 Mn |
| Dec 31, 2022 | -19.63 Mn |
| Sep 30, 2022 | -19.00 Mn |
| Jun 30, 2022 | -19.10 Mn |
| Mar 31, 2022 | -19.80 Mn |
| Dec 31, 2021 | -20.05 Mn |
| Sep 30, 2021 | -17.01 Mn |